论文部分内容阅读
目的探讨丁胺卡那霉素联合头孢哌酮/舒巴坦治疗老年呼吸机相关性肺炎的有效性及安全性。方法选取2011年1月—2013年6月于南充市中心医院收治的老年呼吸机相关性肺炎患者46例,随机分为治疗组24例和对照组22例。治疗组给予丁胺卡那霉素联合头孢哌酮/舒巴坦治疗,对照组给予头孢哌酮/舒巴坦治疗,比较两组临床疗效、细菌疗效和不良反应发生情况。结果治疗组临床有效率、细菌清除率高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论丁胺卡那霉素联合头孢哌酮/舒巴坦治疗老年呼吸机相关性肺炎疗效显著,安全可靠。
Objective To investigate the efficacy and safety of amikacin and cefoperazone / sulbactam in the treatment of senile ventilator-associated pneumonia. Methods Forty-six elderly patients with ventilator-associated pneumonia admitted to Nanchong Central Hospital from January 2011 to June 2013 were randomly divided into treatment group (n = 24) and control group (n = 22). The patients in the treatment group were treated with amikacin and cefoperazone / sulbactam, and the patients in the control group were treated with cefoperazone / sulbactam. The clinical efficacy, bacterial efficacy and adverse reactions were compared between the two groups. Results The clinical effective rate and bacterial clearance rate in the treatment group were higher than those in the control group, with statistical significance (P <0.05). The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Conclusions Amikacin and cefoperazone / sulbactam are effective and safe in the treatment of senile ventilator-associated pneumonia.